Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer

NCT ID NCT04840264

Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase II trial tests a modified combination of three chemotherapy drugs—docetaxel, oxaliplatin, and fluorouracil—in people with advanced stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) and caused a bowel blockage that cannot be surgically removed. The main goal is to see if the treatment can relieve the blockage within 60 days. The study enrolls adults aged 18 to 75 with a performance status up to 3.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
docetaxel, oxaliplatin, and fluorouracil
What this could lead to
If successful, this could offer a way to relieve bowel blockages in advanced gastric cancer patients who cannot have surgery, potentially improving quality of life.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. Chemotherapy side effects can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 79 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-75 years of age; * ECOG PS ≤3; * pathologically diagnosed gastric or gastroesophageal junctional adenocarcinoma; * peritoneal carcinomatosis established by imaging data or pathological evidence; * MBO below the Treitz ligament based on clinical grounds or radiological findings; * considered as inoperable MBO by two independent surgical consultants; * Hb≥60g/L, WBC ≥4×10E9/L, ANC≥2×10E9/L，PLT≥100×10E9/L; * Cr≤ Upper Normal Limit(UNL); * Tbil≤1.5 UNL,AST≤1.5 UNL, ALT≤1.5 UNL, ALP≤1.5 UNL; * Written informed consent form paticipants. Exclusion Criteria: * treated by a combination regimen containing all the study drugs; * allergy to any of the study drugs; * HER-2 amplification or overexpression, mismatch repair protein expression deletion (dMMR), or genetic testing suggestive of high microsatellite instability (MSI-H); * strangulated intestinal obstruction; * active gastrointestinal bleeding; * uncontrolled active infection; * unstable heart diseases with severe ECG abnormalities or affect clinical treatment (such as cardiac insufficiency, myocardial infarction, angina); * severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc); * mental disorders that affect clinical treatment or central nervous system diseases; * concomitant cerebral parenchymal or meningeal metastasis; * HIV infection or untreated active hepatitis; * bowel surgery or stenting required due to obstruction; * pregnant or lactating women; * other conditions that are not suitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma peritoneal carcinomatosis peritoneal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic gastric adenocarcinoma Metastatic gastroesophageal junction adenocarcinoma Peritoneal carcinomatosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.